

Literatura ACTA MEDICINAE 14/2022 Vnitřní lékařství

- 3 **Prediabetes – co znamená pro klinickou praxi**
prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika, 2. LF UK a FN v Motole, Praha
- 3 **Dyslipidemie a diabetes**
MUDr. Martina Nováková | prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika 2. LF UK a FN v Motole, Praha
- 3 **Nové perspektivy antikoagulační léčby, zaměřeno na inhibici vnitřní cesty koagulace**
prof. MUDr. Jan Bultas, CSc. Farmakologický ústav, 3. LF UK, Praha
- 3 **Inhibitory SGLT2 a srdeční selhání**
MUDr. Dominika Tavačová | prof. MUDr. Jan Václavík, Ph.D., FESC Interní a kardiologická klinika, Fakultní nemocnice a Lékařská fakulta Ostravské univerzity, Ostrava
- 3 **Ivabradin v symptomatické léčbě chronické stabilní anginy pectoris a chronického srdečního selhání – kazuistika**
prof. MUDr. Miroslav Souček, CSc. | doc. MUDr. Mojmír Bláha, CSc. II. interní klinika FN u sv. Anny v Brně a LF MU, Brno
- 4 **Kombinační léčba hypertenze (telmisartan s hydrochlorothiazidem) – kazuistika**
prof. MUDr. Miroslav Souček, CSc. | doc. MUDr. Mojmír Bláha, CSc. II. interní klinika FN u sv. Anny v Brně a LF MU, Brno
- 4 **Význam dlouhodobé EKG monitorace v diagnostice a léčbě arytmií**
MUDr. Renata Krausová Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
- 4 **Měření krevního tlaku u pacientů s arytmií pomocí Veroyal DUO CONTROL**
MUDr. Filip Šustr | prof. MUDr. Miroslav Souček, CSc. II. Interní klinika, Fakultní nemocnice u sv. Anny v Brně
- 4 **Terapie fibrilace síní za specifických okolností na jednotce intenzivní péče – kazuistika**
MUDr. Jan Pudil II. interní klinika – klinika kardiologie a angiologie, 1. LF UK a VFN v Praze
- 4 **Ischemická cévní příhoda mozková – rozbor relevantních témat pro internisty**
MUDr. Libor Kameník, Ph.D. | MUDr. Ilja Kotík | MUDr. Mgr. Tomáš Burger Interní klinika 1. LF UK a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha
- 5 **(Nové) indikace a využití drug coated balloon – přehledový článek**
MUDr. Zuzana Komorová | MUDr. Ladislav Groch, Ph.D. | MUDr. Jiří Seménka | prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika, LF MU a Fakultní nemocnice u sv. Anny v Brně
- 6 **Časný rozvoj hypertenze zvyšuje riziko poškození cílových orgánů ve středním věku**
MUDr. Petra Vysočanová, Ph.D. Poradna pro léčbu hypertenze, Interní kardiologická klinika, FN a LF MU, Brno
- 6 **Nedůsledná kontrola arteriální hypertenze u mladých osob přispívá k rozvoji demence ve stáří**
MUDr. Petra Vysočanová, Ph.D. Poradna pro léčbu hypertenze, Interní kardiologická klinika, FN a LF MU, Brno
- 6 **Expertní stanovisko ke spolupráci diabetologů a internistů s nefrology v péči o nemocné s chronickým onemocněním ledvin**
prof. MUDr. Ondřej Viklický, CSc. Klinika nefrologie, Transplantační centrum, IKEM, Praha
prof. MUDr. Romana Ryšavá, CSc. | prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie, VFN a 1. LF UK, Praha
prof. MUDr. Ivan Rychlík, CSc. Interní klinika FNKV a 3. LF UK, Praha
prof. MUDr. Martin Prázný, CSc., Ph.D. | prof. MUDr. Richard Češka, CSc. III. interní klinika VFN a 1. LF UK, Praha
prof. MUDr. Martin Haluzík, DrSc. Centrum diabetologie, IKEM, Praha
- 6 **SÚKL rozhodl o úhradě dapagliflozinu 10 mg pro léčbu chronického onemocnění ledvin u dospělých s diabetem 2. typu i bez něj**
- 7 **Diagnostika a terapie chronické pankreatitidy**
prof. MUDr. Petr Dítě, DrSc. | doc. MUDr. Lumír Kunovský, Ph.D. Interní gastroenterologická klinika Fakultní nemocnice Brno
doc. MUDr. Arnošt Martínek, CSc. | MUDr. Marie Přecechtělová Interní kardiologická klinika Fakultní nemocnice Ostravské univerzity, Ostrava
RNDr. Magdalena Uvírová, Ph.D. CGB Laboratoř, Ostrava
- 7 **Léčba bolesti metamizolem v klinické praxi**
MUDr. Pavlína Nosková, Ph.D. KARIM VFN a 1. LF UK, Praha

7 **Racekadotril v léčbě akutních průjemových onemocnění**

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

7 **Syntroxine – nová léčebná modalita**

MUDr. Dagmar Langová Interní klinika IPVZ, Krajská nemocnice T. Bati, a. s., Zlín

Prediabetes – co znamená pro klinickou praxi

prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika, 2. LF UK a FN v Motole, Praha

- 1 Brannick, B. – Dagogo-Jack, S.: Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. *Endocrinol Metab Clin North Am*, 2018, 47, s. 33–50.
- 2 Česká diabetologická společnost ČDS ČLS JEP: Doporučený postup péče o nemocné s prediabetem. 2012. Dostupné z: https://www.diab.cz/dokumenty/standard_prediabetes.pdf, vyhledáno 19. 6. 2022.
- 3 ČDS a Česká společnost klinické biochemie ČLS JEP: Diabetes mellitus – laboratorní diagnostika a sledování stavu pacientů. 2019. Dostupné z: https://www.diab.cz/dokumenty/standard_labor_2019.pdf, vyhledáno 24. 6. 2022.
- 4 Echouffo-Tcheugui, J. B. – Selvin, E.: Prediabetes and what it means: the epidemiological evidence. *Annu Rev Public Health*, 2021, 42, s. 59–77.
- 5 Esquivel Zuniga, R. – DeBoer, M. D.: Prediabetes in adolescents: prevalence, management and diabetes prevention strategies. *Diabetes Metab Syndr Obes*, 2021, 14, s. 4609–4619.
- 6 Gomes, A. C. – Hoffmann, C. – Mota, J. F.: The human gut microbiota: Metabolism and perspective in obesity. *Gut Microbes*, 2018, 9, s. 308–325.
- 7 Knowler, W. C. – Barrett-Connor, E. – Fowler, S. E., et al.: Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with life style intervention or metformin. *N Engl J Med*, 2002, 346, s. 393–403.
- 8 leRoux, C. W. – Astrup, A. – Fujioka, K., et al.: SCALE Obesity Prediabetes NN8022-1839 Study Group: 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*, 2017, 389, s. 1399–1409.
- 9 National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes*, 1979, 28, s. 1039–1057.
- 10 Richter, B. – Hemmingsen, B. – Metzendorf, M. I., et al.: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. *Cochrane Database Syst Rev*, 2018, 10, CD012661.
- 11 Saeedi, P. – Petersohn, I. – Salpea, P., et al.: IDF Diabetes Atlas Committee: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*, 2019, 157, s. 107843.

Dyslipidemie a diabetes

MUDr. Martina Nováková | prof. MUDr. Milan Kvapil, CSc., MBA Geriatrická interní klinika 2. LF UK a FN v Motole, Praha

- 1 Kvapil, M.: Současné možnosti farmakologické léčby hyperlipidemie u diabetes mellitus 2. typu. *Remedia*, 2004, 14, s. 324–331.
- 2 MRC/BHF. Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*, 2003, 361, s. 2005–2016.
- 3 Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney, P. M. – Blackwell, L. – Collins, R., et al.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*, 2008, 371, s. 117–125.
- 4 Cholesterol Treatment Trialists' Collaboration: Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet*, 2019, 393, s. 407–415.
- 5 Mok, H. Y. – von Bergmann, K. – Grundy, S. M.: Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. *J Lipid Res*, 1979, 20, s. 389–398.
- 6 Okada, K. – Yagyu, H. – Kotani, K., et al.: Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. *Endocr J*, 2010, 57, s. 903–908.
- 7 Ray, K. K. – Landmesser, U. – Leiter, L. A., et al.: Iniclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. *N Engl J Med*, 2017, 376, s. 1430–1440.
- 8 Dostupné z: https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_cs.pdf, vyhledáno 17. 8. 2022.
- 9 Look AHEAD Research Group: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*, 2013, 369, s. 145–154.
- 10 Wilcox, R. – Bousser, M. G. – Betteridge, D. J., et al.: PROactive Investigators: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone Clinical Trial In macroVascular Events 04). *Stroke*, 2007, 38, s. 865–873.
- 11 Erdmann, E. – Dormandy, J. A. – Charbonnel, B., et al.: PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. *J Am Coll Cardiol*, 2007, 49, s. 1772–1780.
- 12 Kernan, W. N. – Viscoli, C. M. – Furie, K. L.; IRIS Trial Investigators: Pioglitazone prevents diabetes or transient ischemic attack. *N Engl J Med*, 2016, 374, s. 1321–1331.
- 13 Inzucchi, S. E. – Viscoli, C. M. – Young, L. H.; IRIS Trial Investigators: Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. *Diabetes Care*, 2016, 39, s. 1684–1692.
- 14 Young, L. H. – Viscoli, C. M. – Schwartz, G. G.; IRIS Investigators: Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. *Circulation*, 2018, 138, s. 1210–1220.

Nové perspektivy antikoagulační léčby, zaměřeno na inhibici vnitřní cesty koagulace

prof. MUDr. Jan Bultas, CSc. Farmakologický ústav, 3. LF UK, Praha

- 1 Naudin, C. – Burillo, E. – Blankenberg, S., et al.: Factor XII contact activation. *Semin Thromb Hemost*, 2017, 43, s. 814–826.
- 2 Grover, S. P. – Mackman, N.: Intrinsic pathway of coagulation and thrombosis insights from animal models. *Arterioscler Thromb Vasc Biol*, 2019, 39, s. 331–338.
- 3 Verhamme, P. – Yi, A. – Segers, A., et al.: Abelaicimab for prevention of venous thromboembolism. *N Engl J Med*, 2021, 385, s. 609–617.
- 4 Weitz, J. I. – Bauersachs, R. – Becker, B., et al.: Effect of osimab in preventing venous thromboembolism among patients undergoing knee arthroplasty. *JAMA*, 2020, 323, s. 130–139.
- 5 Kubitz, D. – Heckmann, M. – Distler, J., et al.: Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study. *Br J Clin Pharmacol*, 2022, doi.org/10.1111/bcp.15230.
- 6 Piccini, J. P. – Caso, V. – Connolly, S. J., et al.: Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. *Lancet*, 2022, 399, s. 1383–1390.
- 7 Perera, V. – Wang, Z. – Luetgen, J., et al.: First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. *Clin Transl Sci*, 2022, 15, s. 330–342.
- 8 Weitz, J. I. – Strony, J. – Ageno, W., et al.: Milvexian for the prevention of venous thromboembolism. *N Engl J Med*, 2021, 385, s. 2161–2172.
- 9 Büller, H. R. – Bethune, C. – Bhanot, S., et al.: Factor XI antisense oligonucleotide for prevention of venous thrombosis. *N Engl J Med*, 2015, 372, s. 232–240.
- 10 Donadini, M. P. – Ageno, W.: Milvexian and other drugs targeting Factor XI: a new era of anticoagulation? *Bleeding, Thrombosis, and Vascular Biology*, 2022, doi.org/10.4081/btvb.2022.22.

Inhibitory SGLT2 a srdeční selhání

MUDr. Dominika Tavačová | prof. MUDr. Jan Václavík, Ph.D., FESC Interní a kardiologická klinika, Fakultní nemocnice a Lékařská fakulta Ostravské univerzity, Ostrava

- 1 Anker, D. A. – Butler, J. – Filippatos, G., et al.: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385, s. 1451–1461.
- 2 Haluzik, M. – Kubičková, M. – Veselý, J., et al.: Expertní konsenzus k praktickým aspektům spolupráce kardiologa a diabetologa v péči o pacienty s chronickým srdečním selháním s redukovanou ejekční frakcí. *Cor Vasa*, 2021, 63, s. 630–636.
- 3 Táborský, M., et al.: *Novinky v kardiologii*. Praha, Mladá fronta, 2019.
- 4 Špinar, J. – Špinarová, L. – Vitovec, J.: Dapagliflozin a srdeční selhání. *Cor Vasa*, 2020, 62, s. 618–623.
- 5 Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. *J Card Fail*, 2022, 28, s. e1–e167.
- 6 Staněk, V., et al.: *Kardiologie v praxi*. Axonite, 2020.
- 7 McMurray, J. J. V. – Solomon, S. D. – Inzucchi, S. E., et al.: DAPA HF Trial Committees and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2019, 381, s. 1995–2008.
- 8 Špinar, J. – Špinarová, L. – Vitovec, J.: EMPEROR-Reduced – empagliflozin u nemocných se srdečním selháním a nízkou ejekční frakcí. *Intervenční a akutní kardiologie*, 2020, 19, s. 238–241.

Ivabradin v symptomatické léčbě chronické stabilní anginy pectoris a chronického srdečního selhání – kazuistika

prof. MUDr. Miroslav Souček, CSc. | doc. MUDr. Mojmír Bláha, CSc. II. interní klinika FN u sv. Anny v Brně a LF MU, Brno

- 1 Špinar, J. – Málek, F. – Špinarová, L. – Vitovec, J. – Táborský, M. – Linhart, A.: Úprava guidelines ACC pro léčbu srdečního selhání v roce 2021. *Cor et Vasa*, 2021, 63, s. 264–270, DOI: 10.33678/cor.2021.033.

Kombinační léčba hypertenze (telmisartan s hydrochlorothiazidem) – kazuistika

prof. MUDr. Miroslav Souček, CSc. | doc. MUDr. Mojmir Bláha, CSc. II. interní klinika FN u sv. Anny v Brně a LF MU, Brno

1 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. *Vnitřní Léč.* 2018, 64, s. 771–796.

Význam dlouhodobé EKG monitorace v diagnostice a léčbě arytmií

MUDr. Renata Krausová Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

- Steinberg, J. S. – Varma, N. – Cygankiewicz, I., et al.: 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. *Heart Rhythm*, 2017, 14, s. e55–e96.
- Locati, E. T. – Vecchi, A. M. – Vargiu, S., et al.: Role of extended external loop recorders for the diagnosis of unexplained syncope, pre-syncope, and sustained palpitations. *Europace*, 2014, 16, s. 914–922.
- Locati, E. T. – Moya, A. – Oliveira, M., et al.: External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study. *EP Europace*, 2016, 18, s. 1265–1272.
- Gladstone, D. J. – Spring, M. – Dorian, P., et al.: EMBRACE Investigators and Coordinators: Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med*, 2014, 370, s. 2467–2477.
- Brignole, M. – Vardas, P. – Hoffmann, E., et al.: Indications for the use of diagnostic implantable and external ECG loop recorders. *Europace*, 2009, 11, s. 671–687.
- Krausová, R., et al.: Význam dlouhodobé EKG monitorace u pacientů s neobjasněnou synkopou – první zkušenosti s implantabilní monitorovací jednotkou Reveal. *Interv Akut Kardiol*, 2003, 2, s. 12–17.
- Camm, A. J. – Simantirakis, E. – Goette, A., et al.: Atrial high-rate episodes and stroke prevention. *Europace*, 2017, 19, s. 169–179.
- Lopes, R. D. – Alings, M. – Connolly, S. J., et al.: Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESIA) trial. *Am Heart J*, 2017, 189, s. 137–145.
- Lau, J., et al.: Performance of an automated iPhone ECG algorithm to diagnose atrial fibrillation in a community AF screening program (SEARCH-AF). *Heart, Lung and Circulation*, 2013, 22, s. S205.
- Sanders, D. – Ungar, L. – Eskander, M. A., et al.: Ambulatory ECG monitoring in the age of smartphones. *Cleveland Clin J Med*, 2019, 86, s. 483–493.
- Tarakji, K. G., et al.: Using a novel wireless system for monitoring patients after the atrial fibrillation ablation procedure: the iTransmit study. *Heart Rhythm*, 2015, 12, s. 554–559.
- Wegner, F. K., et al.: Prospective blinded evaluation of the smartphone-based AliveCor Kardia ECG monitor for atrial fibrillation detection: The PEAK-AF study. *Eur J Intern Med*, 2020, 73, s. 72–75.
- Perez, M. V. – Mahaffey, K. W. – Hedlin, H., et al.: Large-scale assessment of a smartwatch to identify atrial fibrillation. *N Engl J Med*, 2019, 381, s. 1909–1917.
- Andrade, J. G. – MacGillivray, J. – Macle, L., et al.: Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation. *Heart Rhythm*, 2018, 15, s. 9–16.
- Táborský, M. – Kautzner, J. – Fedorco, M., et al.: Jak používat digitální techniku k detekci a monitorování arytmií v péči o jedince s poruchami srdečního rytmu: Praktický návod Evropské asociace srdečního rytmu (EHRA). Překlad dokumentu připravený Českou kardiologickou společností. *Cor Vasa*, 2022, 64, s. 337–358.

Měření krevního tlaku u pacientů s arytmií pomocí Veroyal DUO CONTROL

MUDr. Filip Šustr | prof. MUDr. Miroslav Souček, CSc. II. Interní klinika, Fakultní nemocnice u svaté Anny v Brně

- Widimský, J. – Filipovský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. *Vnitřní Léč.* 2018, 64, s. 771–796.
- Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J*, 2018, 39, s. 3021–3104.
- Ceral, J. – Linhart, A. – Filipovský, J.: Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku. 2. část. Měření krevního tlaku v ordinaci. *Hypertenze & kardiologická prevence*, 2016, 5, s. 28–33.
- Stergiou, G. S. – Palatini, P. – Parati, G., et al.: 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. *J Hypertens*, 2021, 39, s. 1293–1302.
- Linhart, A. – Ceral, J. – Filipovský, J.: Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku. 1. část. Obecné principy. *Hypertenze & kardiologická prevence*, 2016, 5, s. 24–27.
- Zaprutko, T. – Zaprutko, J. – Sprawka, J., et al.: The comparison of Kardia Mobile and Hartmann Veroyal 2 in 1 in detecting first diagnosed atrial fibrillation. *Cardiol J*, 2021, doi: 10.5603/CJ.a2021.0083.

Terapie fibrilace síní za specifických okolností na jednotce intenzivní péče – kazuistika

MUDr. Jan Pudil II. interní klinika – klinika kardiologie a angiologie, 1. LF UK a VFN v Praze

- Imamura, T. – Kinugawa, K.: Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. *ESC Heart Fail*, 2020, 7, s. 2208–2213.
- Wada, Y. – Aiba, T. – Tsujita, Y., et al.: Practical applicability of landiolol, an ultra-short-acting β_1 -selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. *J Arrhythm*, 2016, 32, s. 82–88.
- Kiuchi, S. – Aikawa, H. – Hisatake, S., et al.: Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia. *J Clin Med Res*, 2017, 9, s. 426–432.
- Nagai, R. – Kinugawa, K. – Inoue, H., et al.: J-Land Investigators: Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β_1 -selective blocker landiolol with digoxin (J-Land Study). *Circ J*, 2013, 77, s. 908–916.

Ischemická cévní příhoda mozková – rozbor relevantních témat pro internisty

MUDr. Libor Kameník, Ph.D. | MUDr. Ilja Kotík | MUDr. Mgr. Tomáš Burger Interní klinika 1. LF UK a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha

- ČSSZ. Otevřená data. Počet vyplácených invalidních důchodů v České republice v roce 2020.
- Jing, H. – Wenjing, M. – Jingxianet, N., et al.: Rate and determinants of recurrence at 1 year and 5 years after stroke in a low-income population in rural China. *Front Neurol*, 2020, 11, s. 2.
- Kleindorfer, D. O. – Towfighi, A. – Chaturvedi, S., et al.: 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. *Stroke*, 2021, 52, s. e364–e467.
- Glober, N. K., et al.: Acute stroke: current evidence-based recommendations for prehospital care. *West J Emerg Med*, 2016, 17, s. 104–128.
- Sandset, E. Ch., et al.: European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. *Eur Stroke J*, 2021, 6, s. II, doi: 10.1177/23969873211026998. Odkaz na: *Eur Stroke J*, 2022, 7, s. NP1, PMID: 34780579; PMCID: PMC8370067.
- Kobayashia, A. – Czlonkowska, A. – Ford, G. A., et al.: European Academy of Neurology and European Stroke Organization consensus statement and practical guidance for pre-hospital management of stroke. *Eur J Neurol*, 2018, 25, s. 425–433.
- CMP manuál, www.manual-CMPcz.
- Powers, W. J. – Rabinstein, A. A. – Ackerson, T., et al.: 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for health care professionals from the American Heart Association/American Stroke Association. *Stroke*, 2018, 49, s. e46–e99.
- Sandset, E. C. – Anderson, C. S. – Bath, P. M., et al.: European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intra cerebral haemorrhage. *Eur Stroke J*, 2021, 6, s. X48–L89.
- Goyal, N., et al.: Blood pressure levels post mechanical thrombectomy and outcomes in large vessel occlusion strokes. *Neurology*, 2017, 89, s. 540–547.
- Hemphill, J. C. 3rd – Greenberg, S. M. – Anderson, C. S., et al.: Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for health care professionals from the American Heart Association/American Stroke Association. *Stroke*, 2015, 46, s. 2032–2060.
- Kirtipal, B. – Vardhman, J. – Aggarwal, D., et al.: Stroke. Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack: meta-analysis of randomized controlled trials. *Stroke*, 2021, 52, s. e217–e223.
- Fischer, U. – Baumgartner, A. – Arnold, M., et al.: What is a minor stroke? *Stroke*, 2010, 41, s. 661–666.
- Jauch E. C. – Saver, J. L. – Adams, H. P., et al.: American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*, 2013, 44, s. 870–947.
- Brandel, M. G. – Elawaf, Y. – Rennert, R. C., et al.: Antiplatelet therapy within 24 hours of tPA: lessons learned from patients requiring combined thrombectomy and stenting for acute ischemic stroke. *J Cerebrovasc Endovasc Neurosurg*, 2020, 22, s. 1–7.
- Jiangyun, L. – Xingxing, H., et al.: The safety and effectiveness of early anti-platelet therapy after alteplase for acute ischemic stroke: A meta-analysis. *J Clin Neurosci*, 2021, 91, s. 176–182.
- Xu, Z. – Chen, N., et al.: Dual antiplatelet therapy in patients with minor stroke receiving intravenous thrombolysis. *Front Neurol*, doi: org/10.3389/fneur.2022.819896.
- Berge, E. – Whiteley, W. – Audebert, H., et al.: European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. *Eur Stroke J*, 2021, 6, s. I–ixii.
- Kam, W. – Holmes, D. N. – Hernandez, A. F., et al.: Association of recent use of non-vitamin K antagonist oral anticoagulants with

- intracranial hemorrhage among patients with acute ischemic stroke treated with alteplase. *JAMA*, 2022, 327, s. 760–771.
- 20 **Heidbuechel, H. – Verhamme, P., et al.**: EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. *Eur Heart J*, 2013, 34, s. 2094–2106.
 - 21 **Pacioroni, M. – Agnelli, G. – Falocci, N., et al.**: Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. *Stroke*, 2015, 46, s. 21.
 - 22 **Abdul-Rahim, A. H. – Fulton, R. L., et al.**: VISTA Collaborators: Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. *Eur J Neurol*, 2015, 22, s. 1048–1055.
 - 23 **Seiffge, D. J. – Werring, D. J., et al.**: Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. *Lancet Neurol*, 2019, 18, s. 117–126.
 - 24 **Naidoo, P. – Hift, R.**: Massive pulmonary thromboembolism and stroke. *Case Rep Med*, 2011, doi: 10.1155/2011/398571.
 - 25 **Saleh Velez, F. G. – Ortiz Garcia, J. G.**: Management dilemmas in acute ischemic stroke and concomitant acute pulmonary embolism: Case series and literature review. *eNeurological Sci*, 2021, 23, s. 100341.
 - 26 **Piironen, K. – Putaala, J. – Rosso, C., et al.**: Glucose and acute stroke: evidence for an interlude. *Stroke*, 2012, 43, s. 898–902.
 - 27 **Cerecedo-Lopez, C. D. – Cantu-Aldana, A., et al.**: Insulin in the management of acute ischemic stroke: a systematic review and meta-analysis. *World Neurosurg*, 2020, 136, s. e514–e534.
 - 28 **Ntaios, G. – Egli, M. – Fauzi, M., et al.**: J-shaped association between serum glucose and functional outcome in acute ischemic stroke. *Stroke*, 2010, 41, s. 2366–2370.
 - 29 **Rubiera, M. – Aires, A., et al.**: European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. *Eur Stroke J*, 2022, doi: 10.1177/23969873221099478.
 - 30 **Morhij, D. – Dani, K., et al.**: Sensitivity of transcranial doppler and transoesophageal echocardiography for the detection of patent foramen ovale in cryptogenic stroke. *J Neurol Neurosurg Psychiatry*, 2013, 84, s. e2.
 - 31 **Komar, M. – Olszowska, M., et al.**: Transcranial Doppler ultrasonography should it be the first choice for persistent foramen ovale screening? *Cardiovasc Ultrasound*, 2014, 12, s. 16.
 - 32 **Katsanos, A. H. – Psaltopoulou, T., et al.**: Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis. *Ann Neurol*, 2016, 79, s. 625–635.
 - 33 **Ren, P. – Li, K. – Lu, X., et al.**: Diagnostic value of transthoracic echocardiography for patent foramen ovale: a meta-analysis. *Ultrasound Med Biol*, 2013, 39, s. 1743–1750.
 - 34 **Najjar, R. – Hughes, A.**: Role of transoesophageal echocardiography in detecting patent foramen ovale in stroke patients aged ≤ 60 years: A retrospective study. *PLoS One*, 2020, 15, s. e0242885.
 - 35 **Van der Giessen, H. – Wilson, L., et al.**: Review: Detection of patent foramen ovale using transcranial Doppler or standard echocardiography. *Australas J Ultrasound Med*, 2020, 23, s. 210–219.
 - 36 **Nemer, K. A.**: Atrial septal aneurysm and cryptogenic stroke. *J Saudi Heart Assoc*, 2011, 23, s. 105.
 - 37 **Turc, G. – Lee, J., et al.**: Atrial septal aneurysm, shunt size, and recurrent stroke risk in patients with patent foramen ovale. *J Am Coll Cardiol*, 2020, 75, s. 2312–2320.
 - 38 **Agmon, Y. – Khandheria, B. K. – Meissner, I., et al.**: Frequency of atrial septal aneurysms in patients with cerebral ischemic events. *Circulation*, 1999, 99, s. 1942–1944.
 - 39 **Nakayama, R. – Takaya, Y., et al.**: Identification of high-risk patent foramen ovale associated with cryptogenic stroke: development of a scoring system. *J Am Soc Echocardiogr*, 2019, 32, s. 811–816.
 - 40 **Steven, R., et al.**: Practice advisory update summary: Patent foramen ovale and secondary stroke prevention. Report of the Guideline Subcommittee of the American Academy of Neurology. *Neurology*, 2020, 94, s. 1–10.
 - 41 **Visseren, F. L. J. – Mach, F., et al.**: ESC National Cardiac Societies; ESC Scientific Document Group: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*, 2021, 42, s. 3227–3337.
 - 42 **Dawson, J. – Béjot, Y. – Christensen, L. M., et al.**: European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. *Eur Stroke J*, 2022, doi: 10.1177/23969873221100032.
 - 43 **Bhatt, D. L. – Steg, P. G. – Miller, M., et al.**: REDUCE-IT Investigators: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*, 2019, 380, s. 11–22.
 - 44 **Tanaka, K. – Ishikawa, Y. – Yokoyama, M., et al.**: JELIS Investigators, Japan: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. *Stroke*, 2008, 39, s. 2052–2058.
 - 45 **CAPRIE Steering Committee**: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet*, 1996, 348, s. 1329–1339.
 - 46 **Vidyanti, A. N. – Chan, L. – Lin, C. L., et al.**: Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. *PLoS One*, 2019, 14, s. e0221750.
 - 47 **NASCET North American Symptomatic Carotid Endarterectomy Trial**. Methods, patient characteristics, and progress. *Stroke*, 1991, 22, s. 711–720.
 - 48 **Howard, D. P. J., et al.**: Risk of stroke in relation to degrees of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis. *Lancet Neurol*, 2021, 20, s. 193–202.
 - 49 **Bonati, L. H. – Kakkos, S. – Berkfeldt, J., et al.**: European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. *Eur Stroke J*, 2021, 6, s. 1–XLVII.

(Nové) indikace a využití drug coated balloon – přehledový článek

MUDr. Zuzana Komorová | MUDr. Ladislav Groch, Ph.D. | MUDr. Jiří Seménka | prof. MUDr. Lenka Špinarová, Ph.D., FESC

I. interní kardiologická klinika, LF MU a Fakultní nemocnice u sv. Anny v Brně

- 1 **Lu, W. – Zhu, Y. – Han, Z., et al.**: Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels. *J Cardiol*, 2019, 73, s. 151–155.
- 2 **Rykowska, I. – Nowak, I. – Nowak, R.**: Drug-eluting stents and balloons-materials, structure designs, and coating techniques: a review. *Molecules*, 2020, 25, s. 4624.
- 3 **Costopoulos, Ch. – Latib, A. – Naganuma, T., et al.**: The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease. *JACC Cardiovasc Interv*, 2013, 6, s. 1153–1159.
- 4 **Zbinden, R. – von Felten, S. – Wein, B., et al.**: Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents—a clinical and health-economic valuation. *Cardiovasc Ther*, 2017, 35, s. 19–25.
- 5 **Cheng, G. – Chang, F. J. – Wang, Y., et al.**: Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: a clinical trial based on 1-year follow-up. *Med Sci Monit*, 2019, 25, s. 240–247.
- 6 **Valgimigli, M. – Bueno, H. – Byrne, R. A., et al.**: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*, 2018, 39, s. 213–260.
- 7 **Kibos, A. – Campeanu, A. – Tintoiu, I.**: Pathophysiology of coronary artery in-stent restenosis. *Acute Card Care*, 2007, 9, s. 111–119.
- 8 **Zain, M. A. – Jamil, R. T. – Siddiqui, W. J.**: Neointimal Hyperplasia. 30. 4. 2022. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022, PMID: 29763068.
- 9 **Nusca, A. – Viscusi, M. M. – Piccirillo, F., et al.**: In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. *Life (Basel)*, 2022, 12, s. 393.
- 10 **Herdeg, Ch. – Oberhoff, M. – Baumbach, A., et al.**: Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. *J Am Coll Cardiol*, 2000, 35, s. 1969–1976.
- 11 **Chen, Y. – Zeng, Y. – Zhu, X., et al.**: Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment. *Bioact*, 2021, 6, s. 880–889.
- 12 **Pleva, L.**: Iopromid-paclitaxelové balonkové katetry v koronárních intervencích. *Interv Akut Kardiolog*, 2021, 20, s. 133–138.
- 13 **Ang, H. – Koppa, T. R. – Casese, S., et al.**: Drug-coated balloons: Technical and clinical progress. *Vascular Medicine*, 2020, 25, s. 577–587.
- 14 **Jeger, R. V. – Eccleshall, S. – Ahmad, W. A., et al.**: Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. *JACC Cardiovasc Interv*, 2020, 13, s. 1391–1402.
- 15 **Waksman, R. – Pakala, R.**: Drug-eluting balloon comeback kid? *Circ Cardiovasc Interv*, 2009, 2, s. 352–358.
- 16 **Shin, E. S. – Bang, L. H. – Jun, E. J., et al.**: Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion. *Cardiol J*, 2021, 28, s. 615–622.
- 17 **Navarese, E. P. – Austin, D. – Gurbel, P. A., et al.**: Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. *Clin Res Cardiol*, 2013, 102, s. 279–287.
- 18 **Mates, M. – Němec, P. – Želízko, M., et al.**: Doporučené postupy ESC/EACTS pro revaskularizaci myokardu, 2018. Souhrn dokumentu připravený Českou kardiologickou společností, Českou asociací intervenční kardiologie a Českou společností kardiovaskulární chirurgie ČLS JEP. *Cor Vas*, 2019, 61, s. e123–e156.
- 19 **Tang, Y. – Qiao, S. – Su, X., et al.**: Drug-coated balloon versus drug-eluting stent for small-vessel disease: the RESTORE SVD China randomized trial. *J Am Coll Cardiol Intv*, 2018, 11, s. 2381–2392.
- 20 **Jeger, R. V. – Farah, A. – Ohlow, M. A., et al.**: Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. *Lancet*, 2018, 392, s. 849–856.
- 21 **Jeger, R. V. – Farah, A. – Ohlow, M. A., et al.**: Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. *Lancet*, 2020, 396, s. P1504–P1510.
- 22 **Cortese, B. – Di Palma, G. – Guimaraes, M. G., et al.**: Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. *JACC Cardiovasc Interv*, 2020, 13, s. 2840–2849.
- 23 **Lelasi, A. – Buono, A. – Pellicano, M., et al.**: Hybrid approach evaluating a drug-coated balloon in combination with a new-generation drug-eluting stent in the treatment of de novo diffuse coronary artery disease: The HYPER Pilot Study. *Cardiovasc Revasc Med*, 2021, 28, s. 14–19.
- 24 **Lelasi, A.**: Diffuse Coronary Artery Disease: Restore DCB – the HYPER study. Dostupné z: <https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2021/Diffuse-Coronary-Artery-Disease-RESTORE-DCB-THE-HYPER-STUDY>, vyhledáno 6. 10. 2022.
- 25 **Worthley, S. – Hendriks, R. – Worthley, M., et al.**: Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. *Cardiovasc Revasc Med*, 2015, 16, s. 413–417.
- 26 **Berland, J. – Lefèvre, T. – Brenot, P., et al.**: DANUBIO – a new drug-eluting balloon for the treatment of side branches in bifurcation lesions: six-month angiographic follow-up results of the DEBSIDE trial. *Euro Intervention*, 2015, 11, s. 868–876.
- 27 **Zhang, Y. – Zhang, X. – Dong, Q., et al.**: Duration of dual antiplatelet therapy after implantation of drug-coated balloon. *Front Cardiovasc Med*, 2021, 8, s. 762391.
- 28 **Scheller, B. – Rissanen, T. T. – Farah, A., et al.**: Drug-coated balloon for small coronary artery disease in patients with and without high-bleeding risk in the BASKET-SMALL 2 trial. *Circ Cardiovasc Interv*, 2022, 15, s. e011569.
- 29 **Wöhrle, J. – Scheller, B. – Seeger, J., et al.**: Impact of diabetes on outcome with drug-coated balloons versus drug-eluting stents: The BASKET-SMALL 2 trial. *J Am Coll Cardiol Int*, 2021, 14, s. 1789–1798.
- 30 **Mangner, N. – Farah, A. – Ohlow, M. A., et al.**: BASKET-SMALL 2 Investigators: Safety and efficacy of drug-coated balloons versus drug-eluting stents in acute coronary syndromes: a prespecified analysis of BASKET-SMALL 2. *Circ Cardiovasc Interv*, 2022, 15, s. e011325.
- 31 **Jackson, D. – Tong, D. – Layland, J.**: A review of the coronary applications of the drug coated balloon. *Int J Cardiol*, 2017, 226, s. 77–86.
- 32 **Kokkinidis, D. G. – Waldo, S. W. – Armstrong, E. J.**: Treatment of coronary artery in-stent restenosis. *Expert Rev Cardiovasc Ther*, 2017, 15, s. 191–202.
- 33 **Hu, F. W. – Chang, S. – Li, Q., et al.**: Long-term clinical outcomes after percutaneous coronary intervention with drug-coated balloon-only strategy in de novo lesions of large coronary arteries. *Front Cardiovasc Med*, 2022, 9, s. 882303.
- 34 **Pleva, L. – Kukla, P.**: Sirolimus-eluting balloon catheters. *Interv Akut Kardiolog*, 2020, 19, s. 229–231.
- 35 **Bersin, R. M.**: Update on sirolimus coated balloon technologies. Dostupné z: <https://slideplayer.com/slide/12574739/>, vyhledáno 7. 10. 2022.

Časný rozvoj hypertenze zvyšuje riziko poškození cílových orgánů ve středním věku

MUDr. Petra Vydrošková, Ph.D. Poradna pro léčbu hypertenze, Interní kardiologická klinika, FN a LF MU, Brno

1 Suvila, K. – McCabe, E. L. – Lehtonen, A., et al.: Early onset hypertension is associated with hypertensive end-organ damage already by midlife. *Hypertension*, 2019, HYPERTENSIONAHA11913069.

Nedůsledná kontrola arteriální hypertenze u mladých osob přispívá k rozvoji demence ve stáří

MUDr. Petra Vydrošková, Ph.D. Poradna pro léčbu hypertenze, Interní kardiologická klinika, FN a LF MU, Brno

- 1 Coca, A.: Optimal antihypertensive treatment in prevention and treatment of dementia. 31. kongres ESH, Atény, 19. 6. 2022. Dostupné z: <https://www.eshonline.org/publications/journals/>, vyhledáno 29. 9. 2022.
- 2 GBD 2016 Dementia Collaborators: Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*, 2019, 18, s. 88–106.
- 3 Deckers, K. – van Boxtel, M. P. – Schiepers, O. J., et al.: Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *Int J Geriatr Psychiatry*, 2015, 30, s. 234–246.
- 4 Emdin, C. A. – Rothwell, P. M. – Salimi-Khorshidi, G., et al.: Blood pressure and risk of vascular dementia: evidence from a primary care registry and a cohort study of transient ischemic attack and stroke. *Stroke*, 2016, 47, s. 1429–1435.
- 5 Schrader, B. – Schrader, J. – Elsässer, A., et al.: Influence of cardiovascular risk factors on arterial hypertension and mild cognitive impairment in 4602 participants of the ELITE study. *J Hypertens*, 2020, 38, s. 2475–2481.
- 6 Sierra, C.: Cerebral small vessel disease, cognitive impairment and vascular dementia. *Panminerva Med*, 2012, 54, s. 179–188.
- 7 Sierra, C. – de La Sierra, A. – Mercader, J., et al.: Silent cerebral white matter lesions in middle-aged essential hypertensive patients. *J Hypertens*, 2002, 20, s. 519–524.
- 8 Verhaaren, B. F. – Vernooij, M. W. – de Boer, R., et al.: High blood pressure and cerebral white matter lesion progression in the general population. *Hypertension*, 2013, 61, s. 1354–1359.
- 9 van Middelaar, T. – van Vught, L. A. – van Gool, W. A., et al.: Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis. *J Hypertens*, 2018, 36, s. 1780–1787.
- 10 Forette, F. – Seux, M. L. – Staessen, J. A., et al.: Systolic Hypertension in Europe Investigators: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. *Arch Intern Med*, 2002, 162, s. 2046–2052.
- 11 Yasar, S. – Xia, J. – Yao, W., et al.: Ginkgo Evaluation of Memory (GEM) Study Investigators: Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. *Neurology*, 2013, 81, s. 896–903.
- 12 SPRINT MIND Investigators for the SPRINT Research Group: Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA*, 2019, 321, s. 553–561.
- 13 White, W. B. – Wakefield, D. B. – Moscufo, N., et al.: Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). *Circulation*, 2019, 140, s. 1626–1635.
- 14 Ou, Y. N. – Tan, C. C. – Shen, X. N., et al.: Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. *Hypertension*, 2020, 76, s. 217–225.
- 15 Williams, B. – Mancia, G. – Spiering, W., et al.; Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*, 2018, 36, s. 1953–2041.
- 16 Unger, T. – Borghi, C. – Charchar, F., et al.: 2020 International Society of Hypertension global hypertension practice guidelines. *J Hypertens*, 2020, 38, s. 982–1004.

Expertní stanovisko ke spolupráci diabetologů a internistů s nefrology v péči o nemocné s chronickým onemocněním ledvin

prof. MUDr. Ondřej Viklický, CSc. Klinika nefrologie, Transplantační centrum, IKEM, Praha

prof. MUDr. Romana Ryšavá, CSc. | prof. MUDr. Vladimír Tesař, DrSc. Klinika nefrologie, VFN a 1. LF UK, Praha

prof. MUDr. Ivan Rychlík, CSc. Interní klinika FNKV a 3. LF UK, Praha

prof. MUDr. Martin Prázný, CSc., Ph.D. | prof. MUDr. Richard Češka, CSc. III. interní klinika VFN a 1. LF UK, Praha

prof. MUDr. Martin Haluzík, DrSc. Centrum diabetologie, IKEM, Praha

- 1 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International*, 2013, suppl. 3, s. 1–150.
- 2 Hill, N. R. – Fatoba, S. T. – Oke, J. L., et al.: Global prevalence of chronic kidney disease – a systematic review and meta-analysis. *PLoS One*, 2016, 11, s. e0158765.
- 3 Brück, K. – Stel, V. S. – Gambaro, G., et al.; European CKD Burden Consortium: CKD prevalence varies across the European general population. *J Am Soc Nephrol*, 2016, 27, s. 2135–2147.
- 4 Zima, T. – Racek, J. – Tesaf, V. – Viklický, O., et al.: Doporučení České nefrologické společnosti a České společnosti klinické biochemie ČLS JEP 2014. Doporučení k diagnostice chronického onemocnění ledvin (odhad glomerulární filtrace a vyšetřování proteinurie). Dostupné z: <http://www.nefrol.cz/odbornici/doporucene-postupy-cns>, vyhledáno 13. 10. 2022.
- 5 Smart, N. A. – Dieberg, G. – Ladhani, M., et al.: Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. *Cochrane Database Syst Rev*, 2014, 6, CD007333.
- 6 Cheung, A. K. – Chang, T. I. – Cushman, W. C., et al.: Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int*, 2021, 99, s. 559–569.
- 7 Bakris, G. L. – Agarwal, R. – Anker, S. D., et al. and Investigators F-D: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*, 2020, 383, s. 2219–2229.
- 8 Wanner, C. – Inzucchi, S. E. – Lachin, J. M., et al. and Investigators E-RO: Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*, 2016, 375, s. 323–334.
- 9 Neal, B. – Perkovic, V. – Mahaffey, K. W., et al.; CANVAS Program Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–657.
- 10 Wiviott, S. D. – Raz, I. – Bonaca, M. P., et al. and Investigators D-T: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 11 Heerspink, H. J. L. – Stefánsson, B. V. – Correa-Rotter, R., et al.; DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*, 2020, 383, s. 1436–1446.
- 12 Wheeler, D. C. – Toto, R. D. – Stefánsson, B. V., et al.; DAPA-CKD Trial Committees and Investigators: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. *Kidney Int*, 2021, 100, s. 215–224.
- 13 Jongs, N. – Chertow, G. M. – Greene, T., et al.; DAPA-CKD Trial Committees and Investigators: Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. *J Am Soc Nephrol*, 2022, ASN.2022030306.
- 14 McMurray, J. J. V. – Solomon, S. D. – Inzucchi, S. E., et al.; Committees D-HT and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2019, 381, s. 1995–2008.
- 15 KDIGO 2013: KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. *Kidney Int*, 2013, 3, suppl.
- 16 Anker, S. D. – Butler, J. – Filippatos, G., et al.; EMPEROR-Preserved Trial Investigators: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385, s. 1451–1461.
- 17 Inker, L. A. – Eneanya, N. D. – Coresh, J., et al.; Chronic Kidney Disease Epidemiology Collaboration: New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*, 2021, 385, s. 1737–1749.
- 18 Rychlík, I. – Francová, L.: Statistická ročenka dialyzační léčby v České republice v r. 2021. Česká nefrologická společnost, 2022. Dostupné z: <https://www.nefrol.cz/odbornici/dialyzačni-statistika>, vyhledáno 13. 10. 2022.

SÚKL rozhodl o úhradě dapagliflozinu 10 mg pro léčbu chronického onemocnění ledvin u dospělých s diabetem 2. typu i bez něj

- 1 SPC Forxiga. Dostupné z: www.sukl.cz/modules/medication/detail.php?code=0193660&tab=texts, vyhledáno 12. 10. 2022.
- 2 Státní ústav pro kontrolu léčiv, www.sukl.cz.
- 3 Rozhodnutí sp. zn. SÚKL.S272051/2021, č. j. suk131805/2022, které nabylo právní moci dnem 13. 7. 2022. Dostupné z: <https://www.cisweb.cz/blog/dapagliflozin-lp-forxiga-hrazen-od-182022-pro-lecbu-pacientu-s-ckd>, vyhledáno 12. 10. 2022.
- 4 Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2019. Dostupné z: <https://www.cdc.gov/kidney-disease/publications-resources/2019-national-facts.html>, vyhledáno 12. 10. 2022.
- 5 Segall, L. – Nistor, I. – Covic, A.: Heart failure in patients with chronic kidney disease: a systematic integrative review. *Biomed Res Int*, 2014, 2014, s. 937398.
- 6 Bikbov, B., et al.: Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2020, 395, s. 709–733.
- 7 Jager, K. J., et al.: A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. *Nephrol Dial Transplant*, 2019, 34, s. 1803–1805.
- 8 Heerspink, H. J. L., et al.: Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*, 2020, 383, s. 1436–1446.

Diagnostika a terapie chronické pankreatitidy

prof. MUDr. Petr Dítě, DrSc. | doc. MUDr. Lumír Kunovský, Ph.D. Interní gastroenterologická klinika Fakultní nemocnice Brno
doc. MUDr. Arnošt Martinek, CSc. | MUDr. Marie Přecechtělová Interní kardiologická klinika Fakultní nemocnice Ostravské univerzity, Ostrava

RNDr. Magdalena Uvírová, Ph.D. CGB Laboratoř, Ostrava

- Gardner, T. B. – Kennedy, A. T. – Gelrud, A., et al.: Chronic pancreatitis and its effect on employment and health care experience: results of a prospective American multicenter study. *Pancreas*, 2010, 39, s. 498–501.
- Whitcomb, D. C. – Frulloni, L. – Garg, P., et al.: Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. *Pancreatology*, 2016, 16, s. 218–224.
- Levy, P. – Domínguez-Muñoz, E. – Imrie, C., et al.: Epidemiology of chronic pancreatitis: burden of the disease and consequences. *URG J*, 2014, 2, s. 345–354.
- Barry, K.: Chronic pancreatitis: diagnosis and treatment. *Am Fam Phys*, 2018, 97, s. 385–393.
- Gardner, T. B. – Adler, D. G. – Forsmark, A. C. G., et al.: CCG clinical guideline: Chronic pancreatitis. *Am J Gastroenterol*, 2020, 115, s. 322–339.
- Singh, V. K. – Yadav, D. – Garg, P. K.: Diagnosis and management of chronic pancreatitis: a review. *JAMA*, 2019, 322, s. 2422–2434.
- Kichler, A. – Jang, S.: Chronic pancreatitis: epidemiology, diagnosis, and management updates. *Drugs*, 2020, 80, s. 1155–1168.
- Issa, Y.: Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. *Eur Radiol*, 2017, 27, s. 3820–3844.
- Remer, E. M. – Baker, M. E.: Imaging of chronic pancreatitis. *Radiol Clin North Amer*, 2002, 40, s. 1229–1242.
- Conwell, D. L.: American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. *Alcohol Res*, 2014, 43, s. 1143–1162.
- Balci, C.: MRI and MRCP findings in patients with suspected chronic pancreatitis: correlation with endoscopic pancreatic function testing (ePFT). *J Magn Reson Imaging*, 2011, 17, s. 249–254.
- Lankisch P. G.: Pancreatic ductal abnormalities documented by secretin-enhanced MRCP in asymptomatic subjects with chronic pancreatic hyperenzymemia. *Am J Gastroenterol*, 2010, 105, s. 703–705.
- Iglesias-Garcia, J.: Endoscopic ultrasound in the diagnosis of chronic pancreatitis. *Rev Esp Enferm Dig*, 2015, 107, s. 221–228.
- Gardner, T. B. – Gordon, S. R.: Interobserver agreement for pancreatic endoscopic ultrasonography determined by same day back-to-back examinations. *J Clin Gastroenterol*, 2011, 45, s. 542–545.

Léčba bolesti metamizolem v klinické praxi

MUDr. Pavlína Nosková, Ph.D. KARIM VFN a 1. LF UK, Praha

- Rychlíčková, J. – Jurečková, H.: Metamizol (dipyrone). *Klin Farmakol Farm*, 2021, 35, s. 94–98.
- Nikolova, I. – Petkova, V. – Tencheva, J., et al.: Metamizole: a review profile of a well-known „forgotten” drug part II: clinical profil. *Biotechnol A Biotechnol Eq*, 2013, 27, s. 3605–3619.
- Lejčko, J. – Kozák, J. – Fricová, J. – Sláma, O. – Hakl, M. – Gabrhelík, T.: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, 2016, 19, suppl. 1, www.tigis.cz.
- Rozsivalová, P. – Stíchlauer, R. – Holická, L., et al.: Metamizol v léčbě bolesti u dětské populace. *Pediatr Praxi*, 2020, 21, s. 323–329.
- Nassini, R. – Fusí, C. – Materazzi, S., et al.: The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. *Br J Pharmacol*, 2015, 172, s. 3397–3411.
- Šimiček, M.: Oxfordská liga analgetik a terapie akutní bolesti z pohledu farmaceuta. *Prakt Lékáren*, 2014, 10, s. 166–170.
- Miljković, M. N. – Rančić, N. K. – Šimić, R. M., et al.: Metamizole: current status of the safety and efficacy. *Hospital Pharmacology*, 2018, 5, s. 694–704.
- Kršiák, M. – Doležal, T. – Lejčko, J.: Neopioidní analgetika. In: *Bolest*, 2012, Tigis, Praha, s. 122.
- Kršiák, M.: Farmakoterapie bolestí zad. *Bolest*, 2007, 10, s. 14.
- Informační dopis – Metamizol: Riziko léky indukovaného poškození jater. Dostupné z: <https://www.sukl.cz/leciva/informacni-dopis-metamizol-riziko-leky-indukovaneho>, vyhledáno 13. 7. 2022.
- Metamizol Stada. SPC SÚKL, 2022
- Metamizol – dávkování, použití v těhotenství a během kojení. Dostupné z: <https://www.sukl.cz/metamizol-davkovani-pouziti-v-tehotenstvi-a-behem-kojeni>, vyhledáno 13. 7. 2022.
- Fricová, J. – Hakl, M.: Farmakoterapie nenádorové průlomové bolesti. Metodické pokyny pro farmakoterapii bolesti – speciální část. *Bolest*, 2017, 20, suppl. 1, s. 7.
- Gaertner, J. – Stamer, U. M. – Remi, C., et al.: Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. *Palliat Med*, 2017, 31, s. 26–34.

Racekadotril v léčbě akutních průjmových onemocnění

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- GBD 2016 Diarrhoeal Disease Collaborators: Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis*, 2018, 18, s. 1211–1228.
- Cullen, J. M. – Cascella, M.: Physiology, Enkephalin. Online in: StatPearls. Treasure Island (FL): Stat Pearls Publishing. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK557764/>, vyhledáno 25. 8. 2022.
- Duque-Díaz, E. – Alvarez-Ojeda, O. – Coveñas, R.: Enkephalins and ACTH in the mammalian nervous system. *Vitam Horm*, 2019, 111, s. 147–193.
- Holden, J. E. – Jeong, Y. – Forrest, J. M.: The endogenous opioid system and clinical pain management. *AACN Clin Issues*, 2005, 16, s. 291–301.
- Lecomte, J. M.: An overview of clinical studies with racecadotril in adults. *Int J Antimicrob Agents*, 2000, 14, s. 81–87.
- Hamza, H. – Ben Khalifa, H. – Baumer, P., et al.: Racecadotril versus placebo in the treatment of acute diarrhoea in adults. *Aliment Pharmacol Ther*, 1999, 13, suppl. 6, s. 15–19.
- Fischbach, W. – Andresen, V. – Eberlin, M., et al.: A comprehensive comparison of the efficacy and tolerability of racecadotril with other treatments of acute diarrhoea in adults. *Front Med*, 2016, 3, s. 44.
- Cézar, J. P. – Duhamel, J. F. – Meyer, M., et al.: Efficacy and tolerability of racecadotril in acute diarrhoea in children. *Gastroenterology*, 2001, 120, s. 799–805.
- Vetel, J. M. – Berard, H. – Fretault, N., et al.: Comparison of racecadotril and loperamide in adults with acute diarrhoea. *Aliment Pharmacol Ther*, 1999, 13, suppl. 6, s. 21–26.
- Prado, D.: Global Adult Racecadotril Study Group: A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. *Scand J Gastroenterol*, 2002, 37, s. 656–661.
- Wang, H. H. – Shieh, M. J. – Liao, K. F.: A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. *World J Gastroenterol*, 2005, 11, s. 1540–1543.
- Gallelli, L. – Colosimo, M. – Tolotta, G. A., et al.: Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. *Eur J Clin Pharmacol*, 2010, 66, s. 137–144.
- Duval-Flah, Y. – Berard, H. – Baumer, P., et al.: Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet. *Aliment Pharmacol Ther*, 1999, 13, suppl. 6, s. 9–14.
- Eberlin, M. – Mück, T. – Michel, M. C.: A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. *Front Pharmacol*, 2012, 3, s. 93.

Syntroxine – nová léčebná modalita

MUDr. Dagmar Langová Interní klinika IPVZ, Krajská nemocnice T. Bati, a. s., Zlín

- Suchopár, J. – Prokeš, M. – Suchopár, Š.: Levothyroxin a minimalizace rizik při zajištění klinického účinku. *DMEV*, 2021, 24, 4, s. 175–181.
- Marek, J. – Hána, V., et al.: *Endokrinologie*. Galén, Praha, 2017, s. 257–261.
- Syntroxine, SPC. Dostupné z: <https://www.sukl.cz/download/spc/SPC19645.pdf>, vyhledáno 4. 10. 2022.